On May 3, 2024, Genentech released an update to the SMA community related to Evrysdi® (risdiplam) and Genentech’s activities in service of the SMA community.
Read the full community statement here.
"Many thanks to the entire SMA community who continue to inspire the broad work that we are doing from
research to innovative programming. As always, we welcome your feedback and look forward to seeing many
of you at the Cure SMA annual meeting next month in Austin!"
